Navigation Links
New Data Demonstrate Longer-Term Safety Profile of Esbriet®
Date:9/26/2011

lung transplantation, so we hope that this new longer-term safety data will reinforce the known safety and importance of Esbriet as the future standard of care for patients living with IPF," said Giacomo Di Nepi, InterMune's Senior Vice President and Managing Director, Europe.  "Germany is the first country in Europe where Esbriet is now available to patients, and we are glad to be able to offer now this new treatment opportunity to patients with mild to moderate IPF."

RECAP Study Results

At Week 72 in RECAP, mean exposure to pirfenidone 2403 mg/d across both studies was 2.9 years (range, 1-4); 114 patients had received Esbriet 2403 mg/d for at least three years.  The favorable safety and tolerability profile observed in CAPACITY and other prior clinical trials was confirmed in RECAP.

In RECAP, treatment-emergent adverse events (TEAE) and common adverse events (AEs) were very similar to those reported in CAPACITY:

  • 98 percent of RECAP patients reported at least one TEAE compared to 99 percent in the treatment arm and 98 percent in the placebo arm of the CAPACITY program.
  • In RECAP, 33 percent of patients had a serious TEAE compared to 33 percent in the treatment arm and 31 percent in the placebo arm during CAPACITY.
  • The incidence of common AEs in RECAP was very similar to that observed in CAPACITY and these AEs were generally mild to moderate in severity.  The type and frequency of adverse events were generally consistent with observations from the Phase 3 clinical trials; no new safety signals or trends were observed.
  • The overall incidence of photosensitivity or rash was lower in RECAP than in CAPACITY (20 percent of patients vs. 44 percent). Rash and photosensitivity reactions were more common among patients newly initiating treatment with pirfenidone compared with those who were continuing treatment (28 percent vs. 12 percent); however, the incidence w
    '/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis
2. Inovio Pharmaceuticals Completes PENNVAX™-B HIV Vaccine Phase I Study, Demonstrates Best-in-Class T-Cell Immune Responses
3. Germgard Lighting Demonstrates the Worlds Most Effective Hand Sterilizer to Protect Against Contagion
4. NIH-Funded Study Demonstrates That Patients Receiving New CPR Devices (ResQPOD® and ResQPump™) and Cooling Have Improved Long-Term Brain Function Following Cardiac Arrest
5. New Digital Linear Accelerator Control System Demonstrates Treatment Time Savings of Up to 30 Percent
6. Obese Patients Treated With QNEXA Demonstrated Significant Improvement in Quality of Life
7. Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I
8. New Research Demonstrates High Prevalence of Sexually Transmitted Disease Trichomonas Vaginalis and Potential of New Molecular Test to Improve Detection
9. Topaz Pharmaceuticals Ivermectin Cream In Vitro Data Demonstrates Activity Against Head Lice Eggs
10. Halozymes Ultrafast Insulin Demonstrates Reduced Variability of Insulin Absorption for Type 1 Diabetes Patients Using Insulin Pumps
11. CureFAKtor Pharmaceuticals Demonstrates that Novel Focal Adhesion Kinase (FAK) Inhibitors Decrease Pancreatic Cancer Tumor Blood Flow and Reduce Blood Vessel Density
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014  Wrightington, Wigan ... MDRX ) are delighted to announce WWL,s ... new health information system. The system will be implemented ... the way WWL delivers healthcare in the future. ... record of on-time and on-budget system implementations as well ...
(Date:9/30/2014)... LONDON , Sept. 30, 2014 ... conducting this study is to provide an overview ... global market for protein drugs/therapeutics. The key objective ... direction of protein drugs as an important tool ... report explores present and future strategies within the ...
(Date:9/30/2014)... DENVER , Sept. 30, 2014  According ... "the world of cancer clinical trials is going ... clinical trials and the work of the current ... these types of ,next generation, clinical trials, which ... tomorrow."  The company has been ...
Breaking Medicine Technology:Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 2Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 3Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 4Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 2Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 3Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 4Small Denver Company Pharmatech driving a large revolution in how cancer clinical trials are managed 2
... THOUSAND OAKS, Calif., Jan. 7 Amgen (Nasdaq: AMGN ... Healthcare Conference at 8:00 a.m. Pacific Time on Tuesday, Jan. ... Calif. Amgen Chairman and CEO Kevin Sharer will present ... available over the Internet and can be accessed from Amgen,s ...
... Ariz., Jan. 7 The Providence Service Corporation (Nasdaq: ... Executive Officer, is scheduled to present an overview of the Company,s ... on Monday, January 11, 2010 at The Grand Hyatt Hotel in ... ET. , On Thursday, January 14, 2010, Mr. McCusker ...
Cached Medicine Technology:Amgen to Present at the 28th Annual JP Morgan Healthcare Conference 2Providence Service Corporation to Present at the Sidoti & Company, LLC Micro Cap Conference on Monday, January 11th and at the CJS Securities 'New Ideas for the New Year' Conference on Thursday, January 14th 2
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new blog post explaining ... smokers. , Smoking will always have a negative impact ... best method to find affordable coverage. Insurance brokerage websites ... , Whole life insurance premiums will be fixed ... coverage is permanent, the initial rates are very ...
(Date:10/1/2014)... 01, 2014 Join the more than 80 ... Treatment Center’s first ever charity golf tournament to benefit Project ... eating disorders who cannot afford treatment. The tournament will be ... Eureka, Mo. , The day-long event starts with 10:30 ... and award dinner will begin at 5 p.m. and will ...
(Date:10/1/2014)... 01, 2014 Diet Doc understands that many ... lose weight and their dieting attempts could be easily sabotaged ... hormone diet treatments into their programs as a ... see fast and effective weight loss results, it also allows ... habits to maintain their weight for the future. , Earlier ...
(Date:10/1/2014)... occasion of the Leishmaniasis East Africa Platform meeting, ... leishmaniasis experts, results of a pharmacovigilance or ... carried out by MSF, DNDi, and national partners ... to key decision makers in order to boost ... combination of Sodium Stibogluconate and Paromomycin (SSG&PM) in ...
(Date:10/1/2014)... Today marks the final day prosthodontist Dr. ... Oxnard and Woodland Hills, Calif., is in the southern ... , “Speaking to this group of specialists allows more ... the help and care they deserve,” Dr. Jivraj said. ... work, providing cosmetic dentistry, correcting bite issues, placing implants, ...
Breaking Medicine News(10 mins):Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4Health News:Results of large-scale roll out of combination treatment for kala-azar in Eastern Africa 2Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 2Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 3Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 4Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 5
... ... Facebook group regarding the McNeil Consumer Healthcare recall have drafted a downloadable ... Senators. This letter details unanswered questions of concerned parents as McNeil ... of children,s and infant,s Tylenol, Motrn, Zyrtec and Benadryl. This letter ...
... ... Office-LinX 7.1 Recognized for Exceptional Innovation, , ... Richmond Hill, ON (PRWEB) May 7, 2010 ... 7.1 as a recipient of its 2009 Unified Communications magazine Product of the ...
... , ... Healthcare professionals informed of every milestone leading to regulatory approval for,Alair® and Provenge®, ... ... and consulting company, announces the release of two reports on first-of-a-kind technologies just ...
... of Assisted Living Facilities (ALFs) in Los Angeles showed that ... was associated with declining quality of life and increased depression ... published today in the Journal of the American Geriatrics ... they are unable to live independently, but do not require ...
... risk by up to 40 percent, researchers say , THURSDAY, ... role triglyceride levels might play in heart disease, and finally ... fat to an increased risk of heart trouble. , ... disease prevention efforts, but experts say a new report ...
... National Institutes of Health (NIH) has awarded a $2.7-million ... project with Case Western Reserve University School of Nursing, ... Medical Center in Cleveland to study cognitive impairment in ... Heart, Lung, And Blood Institute runs through Jan. 31, ...
Cached Medicine News:Health News:Facebook Group for McNeil Product Recall Organizes Letter Writing Campaign – Urges Concerned Parents to Contact House of Representatives and Senators 2Health News:Esna Technologies Receives Unified Communications Magazine's 2009 Product of the Year Award 2Health News:Esna Technologies Receives Unified Communications Magazine's 2009 Product of the Year Award 3Health News:Esna Technologies Receives Unified Communications Magazine's 2009 Product of the Year Award 4Health News:Hayes, Inc. Technology Prognosis Team Tracks First-of-a-Kind Technologies 2Health News:Older people in assisted-living facilities sleep poorly 2Health News:Genes Tie Blood Fat to Heart Disease 2Health News:Genes Tie Blood Fat to Heart Disease 3Health News:NIH awards $2.7-million grant to Kent State to study cognitive impairment in heart failure patients 2Health News:NIH awards $2.7-million grant to Kent State to study cognitive impairment in heart failure patients 3
... objective and high power negative lens delivering ... true benefit of this system is ease ... is made possible due to a superior ... bar and individual interpupillary adjustment provides stability ...
23 gauge thin wall irrigation. 25 gauge thin wall aspiration. Angled 30 degree shaft 8 mm from tip to bend. Irrigation tip set 0.5 mm behind aspiration tip. Dual hub construction. Polished finish. Ov...
This specially designed 23 gauge spoon-shaped cannula is connected to a balanced salt solution bottle and with a low-flow of fluid, is designed to allow a controlled cleaning of the stromal interface...
... five legs for extra stability. Adjustable height ... travel 6"). 2" ball bearing swivel hard ... upholstery, available in black vinyl as standard, ... a contoured, padded, upholstered backrest, with vertical ...
Medicine Products: